- Home
- ENGN vs SGHT Comparison
ENGN vs SGHT Comparison
Compare ENGN & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENGN | SGHT |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 379.3M | 193.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ENGN | SGHT |
|---|---|---|
| Price | $7.93 | $8.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $22.71 | $6.66 |
| AVG Volume (30 Days) | ★ 404.7K | 203.7K |
| Earning Date | 12-19-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $76,052,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.65 | $2.03 |
| 52 Week High | $11.14 | $8.80 |
Technical Indicators
Market Signals| Indicator | ENGN | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 63.27 |
| Support Level | $8.05 | $8.00 |
| Resistance Level | $8.47 | $8.73 |
| Average True Range (ATR) | 0.60 | 0.45 |
| MACD | -0.04 | -0.11 |
| Stochastic Oscillator | 19.72 | 75.25 |
Price Performance
Historical ComparisonAbout ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.